Single-dose and steady-state pharmacokinetics of a novel microfluidized suspension of atovaquone in human immunodeficiency virus-seropositive patients

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 3, 1996, Pages 556-560

  Dixon, R ^a,c   Pozniak, A L ^b   Watt, H M ^a   Rolan, P ^a   Posner, J ^a  

^a WELLCOME RESEARCH LABORATORIES   (United Kingdom)

^b KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; CD4 ANTIGEN; COTRIMOXAZOLE; FLUCONAZOLE; ZIDOVUDINE;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID DIET; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RASH; STEADY STATE; SUSPENSION; VERTIGO;

EID: 0030032249     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.3.556     Document Type: Article

References (8)

1. Falloon, J., J. Kovacs, W. T. Hughes, D. O'Neill, M. Polis, R. T. Davey, M. D. Rogers, S. LaFon, I. Feuerstein, D. Lancaster, M. Land, C. Tuazon, M. Dohn, S. Greenberg, H. C. Lane, and H. Mauser. 1991. A preliminary evaluation of 566C80 for the treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome N Engl. J. Med. 325:1534-1538.
2. Hammond, D. J., J. R. Burchell, and M. Pudney. 1985. Inhibition of pyrimidine biosynthesis de novo in Plasmodium falciparum by 2-(4-t-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone in vitro. Mol. Biochem. Parasitol. 14: 97-109.
3. Hughes, W. T., V. L. Gray, W. E. Gutteridge, V. S. Latter, and M. Pudney. 1990. Efficacy of hydroxynaphthoquione 566C80 in experimental Pneumocystis carinii pneumonitis. Antimicrob. Agents Chemother. 34:225-228.
4. Hughes, W. T., W. Kennedy, J. L. Shenep, P. M. Flynn, S. V. Hetheringtou, G. Fulle, D. J. Lancaster, D. S. Stein, S. Palte, D. Rosenbaum, S. H. T. Liao, M. R. Blum, and M. D. Rogers. 1991. Safety and pharmacokinetics of 566C80, a hydroxynaphthoquinone with anti-Pneumocystis carinii activity: a phase I study in human immunodeficiency virus (HIV)-infected men. J. Infect. Dis. 163:843-848.
5. Hughes, W. T., L. Leoung, F. Kramer, S. A. Bozzette, S. Safrin, P. Frame, N. Clumeck, H. Masur, D. Lancaster, C. Chan, J. Lavelle, J. Rosenstock, J. Falloon, J. Feinburg, S. LaFon, M. D. Rogers, and F. Sattler. 1991. Comparison of atovaquone (566C80) with trimethoprim-sulphamethoxazole to treat Pneumocystis corinii pneumonia in patients with AIDS. N. Engl. J. Med. 328: 1521-1527.
6. Huskinson-Mark, J., F. G. Araujo, and J. S. Remington. 1991. Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii J Infect. Dis. 164: 101-171
7. Lavelle, J. P., C. B. Trapnell, A. Byrne, J. Noblin, B. M. Sadler, and M. R. Blum. 1994. The absolute and relative bioavailability of atovaquone (MEPRON®) tablets and suspension after administration to HIV-seropositive human volunteers. Clin. Pharm. Ther. 55:192. (Abstract )
8. Rolan, P. E., A. J. Mercer, B. C. Weatherley, T. Holdich, R. W. Peck, G. Ridout, and J. Posner. 1994. Examination of some factors responsible for a food-induced increase in absorption of atovaquone. Br. J. Clin. Pharmacol 37:13-20